SFTPB and interstitial lung disease: Consistently, according to receiver operating characteristic (ROC) curve analysis, SFTPB in serum EVs was superior to serum KL-6 and SP-D in predicting future ILD progression within 1 year (AUC: 0.68 versus 0.51 and 0.63, respectively).